Pharmaceutical compositions and methods of treating dry eye disorders

Abstract

Ophthalmic compositions comprising Inhibitors of Janus kinase-3 (“Jak3”) are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

What is claimed is: 
     
         1 . A topical ophthalmic composition comprising a pharmaceutically effective amount of a Jak3 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         2 . The topical ophthalmic composition of  claim 1 , wherein the Jak3 inhibitor is 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550), and has the structure: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The ophthalmic composition of  claim 2 , wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.0001 to less than 0.1% (w/w). 
     
     
         4 . The ophthalmic composition of  claim 1 , wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.003 to 0.03% (w/w). 
     
     
         5 . The ophthalmic composition of  claim 1 , wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.01 to 0.03% (w/w). 
     
     
         6 . The ophthalmic composition of  claim 2 , wherein the buffer maintains a target pH within the range of pH 5 to 8. 
     
     
         7 . The ophthalmic composition of  claim 2 , further comprising a tonicity agent and a buffer selected from phosphate or citrate. 
     
     
         8 . The ophthalmic composition according to  claim 7 , further comprising a surfactant. 
     
     
         9 . The ophthalmic composition according to  claim 8 , wherein the surfactant is tyloxapol. 
     
     
         10 . A topical ophthalmic composition comprising a pharmaceutically effective amount of the Jak3 inhibitor 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550), or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         and a pharmaceutically acceptable carrier. 
       
     
     
         11 . The ophthalmic composition of  claim 10 , wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.0001 to less than 0.1% (w/w). 
     
     
         12 . The ophthalmic composition of  claim 10 , wherein the pharmaceutically effective amount of Jak3 inhibitor is about 0.03% (w/w). 
     
     
         13 . The ophthalmic composition of  claim 11 , wherein the buffer maintains a target pH within the range of pH 5 to 8. 
     
     
         14 . The ophthalmic composition of  claim 13 , further comprising a tonicity agent and a buffer selected from phosphate or citrate, and a surfactant. 
     
     
         15 . The ophthalmic composition according to  claim 14 , wherein the surfactant is tyloxapol.